Request Demo
Selecta narrows focus to gout drug, freezing rest of pipeline
Phase 3Gene TherapyImmunotherapyPhase 2
Selecta Biosciences "remains committed" to SEL-212, which Selecta still hopes to submit to the FDA for approval as a chronic refractory gout treatment next year.
Selecta Bioscienceslaying off a quarter of SEL-212kforce, Selecta Biosciences is now halting inFDAtment in all but onchronic refractory goutprograms to eke out enough cash into 2027.
The company “remains committed” to its Swedish Orphan BiovSelecta Bioscienceset SEL-212, which Selecta still hopes to submit to the FDA for approval as a chronic refractory gout treatment next year.
The drug is a formulation of the immunoSwedish Orphan Biovitrum and biodegradablSEL-212articlesSelectaulating the immunomodulator raFDAycin that the biotechronic refractory goutently hit the primary endpoint in a pair of phase 3 trials that suggest potential to take on Horizon Therapeutics’ gout drug Krystexxa.
The rest of Selecta’s suite of candidates won’t be spegadricaseth the biotech announcing today that development will now be pausedrapamycinmbination ImmTOR-IL program, which had been on track to begin preclinical studies later this year to set up the drug for entering tHorizon Therapeuticsadgoutn hopiKrystexxalore the drug’s potential in a variety of autoimmune indications, starting with the liver.
“The company is currently assessing ways to support the development of this program through potential partnerships,” Selecta said in the release.
Analysts had held out hope that Selecta would stick with the ImmTOR-IL program, with Mizuho’s Uy Ear suggesting back in May that prioritizing “ImmTOR-IL for T-cell mediated autoimmune liver diseases would provide multiple shots on goal.”
However, Selecta will continue working on Xork, an IgG protease candidate that Astellas licensed in January to develop with the Japanese pharmaImmTOR-ILheapy for Pomediated autoimmune liver diseases
“Our actions today will allow us to preserXorkapitaIgG proteasein our stockholdAstellaserest in [SEL-212] without the dilution that would have been required to suPompe diseaseelopment of our pipeline assets over the long term,” CEO Carsten Brunn, Ph.D., said in the release. “While we believe that our pipeline programs represent great potential, we intend to pursue partnership opportunities to advance the balance of our portfolio and maximize their value.”
The company had already sidelined SEL-302 in May, with Selecta reiterating today that it’s hopingSEL-212d a partner for the asset. The AAV gene therapy is in a phase 1/2 trial in combination with ImmTOR for the treatment of an inherited disorder called methylmalonic acidemia.
At the time, the biotech also madeSEL-302cision to lay Selecta of its workforce as part of cost-cutting measure to keep cash flowing into the second half of 2025. Selecta ended June with $115 million in cash and equivalents, whinherited disorderits latemethylmalonic acidemiad money coming in from Sobi—it now expects to last through to 2027.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.